CJC 1295 + Ipamorelin

Product Overview

CJC 1295 and Ipamorelin are two synthetic peptides studied in scientific research for their interactions with growth hormone signalling pathways. CJC 1295 is an analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor agonist.

This dual-peptide formulation contains 5mg of each compound and is of interest in laboratory research investigating endocrine signalling, peptide interactions and growth hormone regulation.

Manufacturing

CJC 1295 and Ipamorelin can be synthesised using advanced solid-phase peptide synthesis (SPPS) techniques to achieve precise peptide sequences and consistent composition.

Each batch undergoes independent third-party testing to assess peptide identity and purity, with laboratory results. 

The formulation is carefully handled and packaged to help maintain product integrity throughout storage and transport.

Research Applications

CJC 1295 + Ipamorelin is of interest in scientific research exploring:

• Growth Hormone Signalling: Investigation of pathways involved in growth hormone secretion and regulation.

• Endocrine Research: Examination of hormonal signalling mechanisms and receptor interactions.

• Cellular Metabolism: Research into the relationship between growth hormone pathways and metabolic regulation.

• Peptide Interactions: Investigation of the combined activity of GHRH analogues and growth hormone secretagogues.

• Receptor Activity: Studies examining peptide binding, receptor selectivity and downstream cellular signalling.

Disclaimer

For research purposes only. Not for human consumption.